Ledipasvir

From Ganfyd

Jump to: navigation, search
rINN: Ledipasvir
Other Names
GS-5885, methyl N-[(2S)-1- [(6S)-6- [5- [9,9-difluoro- 7-[2- [(1S,2S,4R)-3- [(2S)-2-( methoxycarbonylamino)-3- methylbutanoyl] -3-azabicyclo[2.2.1] heptan-2-yl]-3H- benzimidazol-5-yl] fluoren-2-yl]-1H- imidazol-2-yl]-5- azaspiro[2.4] heptan-5-yl]- 3-methyl-1- oxobutan-2-yl] carbamate
Pharmacological Information
Pharmacology Images
File:LedipasvirMolecule.png
Ledipasvir Molecule
Web information on Ledipasvir
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Other Wikis
Wikipedia on Ledipasvir (Less technical, ? quality control)

Contents

Introduction

Ledipasvir is an antiviral in development for hepatitis C. The ION1-3 series of clinical trials are yet to be published but it is reported that in combination with sofosbuvir virological response in HCV genotype 1 infections was over 90%.

Clinical Use

Indications

Administration

Oral

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

Special advice

Pharmacology

Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.

Personal tools